Home
overview

Diabetes represents a large and growing unmet medical need, with more than 194 million people worldwide afflicted by the disease. New technologies and drug classes for the treatment of diabetes are continuously being developed and as a result the market is brimming with opportunities and increased competition.

In our 7th Annual conference, SMi will bring together, once again, leading industry experts to discuss current movements and projections in the market, challenges and limitations of existing therapies and pipeline activities, with a focus on the opportunities for new and innovative treatments. You will hear the latest case studies from leading companies in the field, discussing their R&D activities and potential market launches. Learning how to be successful in this competitive market, this conference will provide you with an analysis of new drug classes and targets in development including, GLP1 agonists, DPP4 inhibitors, TZD’s and new approaches to insulin resistance and delivery. As current blockbuster drugs approach their patent expiry, this conference will include presentations from industry, academia and specialist companies as they discuss the future of diabetes treatment.

A unique opportunity to learn from leading industry experts including:

  • Dr Cynthia Arbeeny, Vice President, Endocrine & Metabolic Diseases, Genzyme
  • Dr Richard Carr, Vice President, Discovery Management, Novo Nordisk
  • Dr Sekhar Boddupalli, Vice President, Discovery, Galileo Pharmaceuticals
  • Dr Cord Dohrmann, Chief Scientific Officer, Develogen
  • Dr Moh Tadayyon, Group Leader, Boehringer-Ingelheim
  • Dr Monique Berwaer, Principal Scientist & Team Leader, Johnson & Johnson
  • Lotte Bjerre Knudsen, Director, Novo Nordisk
  • Dr Didier Saur, European Medical Director, MDS Pharma Services

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Cord Dohrmann

Cord Dohrmann, Chief Scientific Officer, Develogen

9:10 GLUCOKINASE ACTIVATORS FOR THE TREATMENT OF TYPE 2 DIABETES

Joseph Grimsby

Joseph Grimsby, Senior Research Leader, F. Hoffmann-La Roche

9:50 THE METABOLIC SYNDROME

Cynthia Arbeeny

Cynthia Arbeeny, Vice President Endocrine & Metabolic Diseases, Genzyme

  • Inter-relationship of risk factors leading to diabetes, stroke and cardiovascular disease
  • Genetic and environmental factors underlying insulin resistance
  • Role of marconutrient dysregulation, oxidative stress and inflammation in disease progression
  • Current approaches and limitation of existing therapies, need for polypharmacy
  • Opportunities for intervention: Is there a "magic bullet"?
  • 10:30 Morning Coffee

    11:00 TARGETING INSULIN RESISTANCE

    Cord Dohrmann

    Cord Dohrmann, Chief Scientific Officer, Develogen

  • Insulin resistance and T2D
  • Adipose tissue and insulin resistance
  • Screening for novel targets
  • DG70 a novel kinase regulating insulin sensitivity
  • Development of DG70 kinase inhibitors
  • 11:40 11 BETA HYDROXYSTEROID DESHYDROGENASE

    Monique Berwaer

    Monique Berwaer, Principal Scientist/ Team Leader, Johnson & Johnson

  • 11 b HSD in animal models
  • KO and transgenic model
  • Small molecule inhibitors known
  • Conclusion on therapeutic potential
  • 12:20 Networking Lunch

    13:50 DISCOVERY OF N-(5-HYDROXYADAMANTYL) PHENYLACETAMIDES AS POTENT, SELECTIVE, AND CELLULARLY ACTIVE INHIBITORS OF 11ß- HYDROXYSTEROID DEHYDROGENASE TYPE 1

    Joannes Linders

    Joannes Linders, Principal Scientist, Johnson & Johnson

  • HTS and cellular screening
  • In vivo inhibition of HSD1
  • Structure activity relationship
  • Metabolism
  • In vivo activity
  • 14:30 CHALLENGES IN THE CLINICAL DEVELOPMENT OF A DRUG IN DIABETES

    Didier Saur

    Didier Saur, European Medical Director, MDS Pharma Services

  • Pitfalls in selection criteria, endpoints definition and study design
  • Where to perform which study?
  • Biomarkers: which one(s)? when?
  • Studies in specific patient populations
  • Diabetes and cardiovascular risk: outcome studies
  • 15:10 Afternoon Tea

    15:40 OXIDATIVE STRESS AND ANTIOXIDANT THERAPY IN DIABETES

    Mustafa Lokhandwala

    Mustafa Lokhandwala, Executive Vice Dean for Research, University of Houston

  • Association between oxidative stress, aging and insulin resistance
  • Hyperglycemia-induced oxidative stress and diabetic complications
  • Antioxidant therapy for diabetic complications
  • Oxidative stress and receptor G-protein uncoupling
  • Antioxidants and restoration of drug responsiveness
  • Antioxidant properties of anti-diabetic agents
  • 16:20 LIRAGLUTIDE

    Lotte Bjerre Knudsen

    Lotte Bjerre Knudsen, Director, Novo Nordisk

  • Discovery of Liraglutide
  • Preclinical efficacy of Liraglutide
  • Clinical efficacy of Liraglutide
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Richard Carr

    Richard Carr, Vice President, Discovery Management, Novo Nordisk

    9:10 A DIRECT INHIBITOR OF GLUCONEOGENESIS FOR THE TREATMENT OF TYPE 2 DIABETES

    Paul van Poelje

    Paul van Poelje, Director, Biochemistry, Metabasis Therapeutics

  • Contribution of gluconeogenesis to postprandial and fasting hypeglycemia
  • Fructose 1,6-bisphosphatase, a key regulatory enzyme
  • Design of allosteric inhibitors of fructose 1,6-bisphosphatase
  • In vivo mechanism of action of MB06322
  • mechanism of action of MB06322
  • Anti-diabetic activity of MB06322 in the ZDF rat
  • Combination studies of MB06322 and TZD’s in the ZDF rat
  • Comparison of MB06322 to other anti-diabetic agents
  • 9:50 CONSEQUENCES OF ANTI-DIABETIC THERAPY ON CARDIOVASCULAR RISK

    Richard Carr

    Richard Carr, Vice President, Discovery Management, Novo Nordisk

  • Cardiovascular risks in type 2 diabetic subjects
  • Effects of current therapies for type 2 diabetes on cardiovascular risk factors
  • Effects of newly emerging therapies for type 2 diabetes on cardiovascular risk factors
  • Conclusion and future perspectives
  • 10:30 Morning Coffee

    11:00 IMPROVED MONITORING OF DIABETIC NEPHROPATHY

    Martin Shaw

    Martin Shaw, Senior Product Manager, Biotrin International

  • Diabetic nephropathy is the commonest cause of renal failure
  • Earlier detection of renal effects of therapy
  • Differentiation between diabetic nephropathy and nephrotoxicity
  • Organ and tissue specific biomarkers
  • 11:40 TARGETING SUB-CLINICAL INFLAMMATION

    Sekhar Boddupalli

    Sekhar Boddupalli, Vice President, Discovery, Galileo Pharmaceuticals

  • Rapid identification of conserved inflammatory pathway modulators
  • In vitro pharmacology data on first-in-class leads against clinically validated inflammation targets
  • Preclinical efficacy data with anti-inflammatory leads in animal models of diabetes
  • 12:20 Networking Lunch

    14:00 APPLICATIONS OF LIPIDOMICS IN DIABETES RESEARCH AT PRE-CLINICAL AND CLINICAL LEVEL

  • Systems biology approaches for characterisation of pre-clinical models
  • Context-dependent mining of life science and biomedical data
  • Metabolomics and lipidomics platforms for pre-clinical and clinical research and biomarker discovery
  • Matej Oresic

    Matej Oresic, Principle Investigator, Systems Biology & Bioinformatics, VTT Biotechnology

    Catherine Bounsaythip

    Catherine Bounsaythip, Senior Research Scientist, VTT Biotechnology

    14:40 THE LINK BETWEEN FATTY ACID AND GLUCOSE METABOLISM

    Louis Havekes

    Louis Havekes, Senior Research Scientist, TNO Pharma

  • Lipoprotein metabolism fundamental to fatty acid metabolism
  • Fatty acid fluxes determine adipogenesis and hepatic steatosis
  • Fatty acid partitioning and insulin sensitivity
  • Fatty acid partitioning and insulin sensitivity
  • Fatty acid partitioning and insulin sensitivity
  • Fatty acid partitioning and insulin sensitivity
  • Fatty acid partitioning and insulin sensitivity
  • Lessons from animal models
  • 15:20 NOVEL GPCR TARGETS FOR DIABETES

  • The use of constitutively active receptors in high throughput screens to identify inverse agonists to validate GPCR targets
  • Examples and demonstration of how this approach was used to validate receptors for diabetes
  • Dominic Behan

    Dominic Behan, Chief Scientific Officer, Arena Pharmaceuticals

    James Leonard

    James Leonard, Director, Diabetes & Metabolism, Arena Pharmaceuticals

    16:00 Chairman’s Closing Remarks Followed by Afternoon Tea

    +

    Workshops

    Diabetes Today
    Workshop

    Diabetes Today

    Jurys Great Russell Street Hotel
    5th October 2005
    London, United Kingdom

    Jurys Great Russell Street Hotel

    16-22 Great Russell Street
    London WC1B 3NN
    United Kingdom

    Jurys Great Russell Street Hotel

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.